Genetic predictors of fatigue in prostate cancer patients treated with androgen deprivation therapy: Preliminary findings

Brain, Behavior, and Immunity

Volumn 26, Issue 7, 2012, Pages 1030-1036

  Jim, Heather S L ^a   Park, Jong Y ^a   Permuth Wey, Jennifer ^a   Rincon, Maria A ^b   Phillips, Kristin M ^a   Small, Brent J ^b   Jacobsen, Paul B ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Fatigue; Polymorphism; Prostatic neoplasms; Single nucleotide

Indexed keywords

GOSERELIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEUPRORELIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; BLOOD; CANCER FATIGUE; CANCER PATIENT; CENTER FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; CONTROLLED STUDY; DEPRESSION; DNA EXTRACTION; FATIGUE SYMPTOM INVENTORY; GENE FREQUENCY; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSTATE CANCER; RATING SCALE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY;

AGED; AGED, 80 AND OVER; ALLELES; ANDROGEN ANTAGONISTS; ANDROGENS; CONFIDENCE INTERVALS; DEMOGRAPHY; DEPRESSION; DNA; FATIGUE; GENOTYPE; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84865643097     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2012.03.001     Document Type: Review

References (67)

1. Abraham L.J., Kroeger K.M. Impact of the -308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease. J. Leukoc. Biol. 1999, 66:562-566.
2. Ahlberg K., Ekman T., Gaston-Johansson F. Levels of fatigue compared to levels of cytokines and hemoglobin during pelvic radiotherapy: a pilot study. Biol. Res. Nurs. 2004, 5:203-210.
3. Akaza H. Combined androgen blockade for prostate cancer: review of efficacy, safety and cost-effectiveness. Cancer Sci. 2011, 102:51-56.
4. Aouizerat B.E., Dodd M., Lee K., West C., Paul S.M., Cooper B.A., Wara W., Swift P., Dunn L.B., Miaskowski C. Preliminary evidence of a genetic association between tumor necrosis factor alpha and the severity of sleep disturbance and morning fatigue. Biol. Res. Nurs. 2009, 11:27-41.
5. Baker F., Denniston M., Smith T., West M.M. Adult cancer survivors: how are they faring?. Cancer 2005, 104:2565-2576.
6. Beeber L., Shea J., McCorkle R. The Center for Epidemiological Studies Depression Scale as a measure of depressive symptoms in newly diagnosed patients. J. Psychosoc. Oncol. 1998, 16:1-20.
7. Bellido T., Jilka R.L., Boyce B.F., Girasole G., Broxmeyer H., Dalrymple S.A., Murray R., Manolagas S.C. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J. Clin. Invest. 1995, 95:2886-2895.
8. Bennermo M., Nordin M., Lundman P., Boqvist S., Held C., Samnegard A., Ericsson C.G., Silveira A., Hamsten A., Nastase M.M., Tornvall P. Genetic and environmental influences on the plasma interleukin-6 concentration in patients with a recent myocardial infarction: a case-control study. J. Interferon Cytokine Res. 2011, 31:259-264.
9. Benten W.P., Lieberherr M., Giese G., Wrehlke C., Stamm O., Sekeris C.E., Mossmann H., Wunderlich F. Functional testosterone receptors in plasma membranes of T cells. FASEB J. 1999, 13:123-133.
10. Benten W.P., Lieberherr M., Stamm O., Wrehlke C., Guo Z., Wunderlich F. Testosterone signaling through internalizable surface receptors in androgen receptor-free macrophages. Mol. Biol. Cell 1999, 10:3113-3123.
11. Bluthe R.M., Pawlowski M., Suarez S., Parnet P., Pittman Q., Kelley K.W., Dantzer R. Synergy between tumor necrosis factor alpha and interleukin-1 in the induction of sickness behavior in mice. Psychoneuroendocrinology 1994, 19:197-207.
12. Boiardi L., Casali B., Farnetti E., Pipitone N., Nicoli D., Cantini F., Macchioni P., Bajocchi G., Catanoso M.G., Pulsatelli L., Consonni D., Salvarani C. Relationship between interleukin 6 promoter polymorphism at position -174, IL-6 serum levels, and the risk of relapse/recurrence in polymyalgia rheumatica. J. Rheumatol. 2006, 33:703-708.
13. Bower J.E., Ganz P.A., Aziz N., Fahey J.L. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom. Med. 2002, 64:604-611.
14. Bower J.E., Ganz P.A., Aziz N., Olmstead R., Irwin M.R., Cole S.W. Inflammatory responses to psychological stress in fatigued breast cancer survivors: relationship to glucocorticoids. Brain Behav. Immun. 2007, 21:251-258.
15. Bower J.E., Ganz P.A., Irwin M.R., Arevalo J.M., Cole S.W. Fatigue and gene expression in human leukocytes: increased NF-kappaB and decreased glucocorticoid signaling in breast cancer survivors with persistent fatigue. Brain Behav. Immun. 2011, 25:147-150.
16. Bower J.E., Ganz P.A., Tao M.L., Hu W., Belin T.R., Sepah S., Cole S., Aziz N. Inflammatory biomarkers and fatigue during radiation therapy for breast and prostate cancer. Clin. Cancer Res. 2009, 15:5534-5540.
17. Breitbart W., Alici Y. Psychostimulants for cancer-related fatigue. J. Natl. Compr. Canc. Netw. 2010, 8:933-942.
18. Broeckel J.A., Jacobsen P.B., Horton J., Balducci L., Lyman G.H. Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J. Clin. Oncol. 1998, 16:1689-1696.
19. Brull D.J., Montgomery H.E., Sanders J., Dhamrait S., Luong L., Rumley A., Lowe G.D., Humphries S.E. Interleukin-6 gene -174g>c and -572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler. Thromb. Vasc. Biol. 2001, 21:1458-1463.
20. Collado-Hidalgo A., Bower J.E., Ganz P.A., Cole S.W., Irwin M.R. Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin. Cancer Res. 2006, 12:2759-2766.
21. Collado-Hidalgo A., Bower J.E., Ganz P.A., Irwin M.R., Cole S.W. Cytokine gene polymorphisms and fatigue in breast cancer survivors: early findings. Brain Behav. Immun. 2008, 22:1197-1200.
22. D'Agostino P., Milano S., Barbera C., Di Bella G., La Rosa M., Ferlazzo V., Farruggio R., Miceli D.M., Miele M., Castagnetta L., Cillari E. Sex hormones modulate inflammatory mediators produced by macrophages. Ann. NY Acad. Sci. 1999, 876:426-429.
23. Fishman D., Faulds G., Jeffery R., Mohamed-Ali V., Yudkin J.S., Humphries S., Woo P. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J. Clin. Invest. 1998, 102:1369-1376.
24. Garcia J.M., Li H., Mann D., Epner D., Hayes T.G., Marcelli M., Cunningham G.R. Hypogonadism in male patients with cancer. Cancer 2006, 106:2583-2591.
25. Garg R., Wollan M., Galic V., Garcia R., Goff B.A., Gray H.J., Swisher E. Common polymorphism in interleukin 6 influences survival of women with ovarian and peritoneal carcinoma. Gynecol. Oncol. 2006, 103:793-796.
26. Geinitz H., Zimmermann F.B., Stoll P., Thamm R., Kaffenberger W., Ansorg K., Keller M., Busch R., van Beuningen D., Molls M. Fatigue, serum cytokine levels, and blood cell counts during radiotherapy of patients with breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 2001, 51:691-698.
27. Gornstein R.A., Lapp C.A., Bustos-Valdes S.M., Zamorano P. Androgens modulate interleukin-6 production by gingival fibroblasts in vitro. J. Periodontol. 1999, 70:604-609.
28. Greenberg D.B., Gray J.L., Mannix C.M., Eisenthal S., Carey M. Treatment-related fatigue and serum interleukin-1 levels in patients during external beam irradiation for prostate cancer. J. Pain Symptom Manage. 1993, 8:196-200.
29. Hann D., Winter K., Jacobsen P. Measurement of depressive symptoms in cancer patients: evaluation of the Center for Epidemiological Studies Depression Scale (CES-D). J. Psychosom. Res. 1999, 46:437-443.
30. Hann D.M., Denniston M.M., Baker F. Measurement of fatigue in cancer patients: further validation of the Fatigue Symptom Inventory. Qual. Life Res. 2000, 9:847-854.
31. Hann D.M., Jacobsen P.B., Azzarello L.M., Martin S.C., Curran S.L., Fields K.K., Greenberg H., Lyman G. Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory. Qual. Life Res. 1998, 7:301-310.
32. Hulkkonen J., Pertovaara M., Antonen J., Pasternack A., Hurme M. Elevated interleukin-6 plasma levels are regulated by the promoter region polymorphism of the IL6 gene in primary Sjogren's syndrome and correlate with the clinical manifestations of the disease. Rheumatology (Oxford) 2001, 40:656-661.
33. Jacobsen P.B., Donovan K.A., Vadaparampil S.T., Small B.J. Systematic review and meta-analysis of psychological and activity-based interventions for cancer-related fatigue. Health Psychol. 2007, 26:660-667.
34. Kanda N., Tsuchida T., Tamaki K. Testosterone inhibits immunoglobulin production by human peripheral blood mononuclear cells. Clin. Exp. Immunol. 1996, 106:410-415.
35. Kelley K.W., Bluthe R.M., Dantzer R., Zhou J.H., Shen W.H., Johnson R.W., Broussard S.R. Cytokine-induced sickness behavior. Brain Behav. Immun. 2003, 17(Suppl 1):S112-S118.
36. Khosla S., Atkinson E.J., Dunstan C.R., O'Fallon W.M. Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. J. Clin. Endocrinol. Metab. 2002, 87:1550-1554.
37. Kote-Jarai Z., Easton D.F., Stanford J.L., Ostrander E.A., Schleutker J., Ingles S.A., Schaid D., Thibodeau S., Dork T., Neal D., Donovan J., Hamdy F., Cox A., Maier C., Vogel W., Guy M., Muir K., Lophatananon A., Kedda M.A., Spurdle A., Steginga S., John E.M., Giles G., Hopper J., Chappuis P.O., Hutter P., Foulkes W.D., Hamel N., Salinas C.A., Koopmeiners J.S., Karyadi D.M., Johanneson B., Wahlfors T., Tammela T.L., Stern M.C., Corral R., McDonnell S.K., Schurmann P., Meyer A., Kuefer R., Leongamornlert D.A., Tymrakiewicz M., Liu J.F., O'Mara T., Gardiner R.A., Aitken J., Joshi A.D., Severi G., English D.R., Southey M., Edwards S.M., Al Olama A.A., Eeles R.A. Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. Cancer Epidemiol. Biomarkers Prev. 2008, 17:2052-2061.
38. Kroeger K.M., Carville K.S., Abraham L.J. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol. Immunol. 1997, 34:391-399.
39. Kroeger K.M., Steer J.H., Joyce D.A., Abraham L.J. Effects of stimulus and cell type on the expression of the -308 tumour necrosis factor promoter polymorphism. Cytokine 2000, 12:110-119.
40. Kyrdalen A.E., Dahl A.A., Hernes E., Hem E., Fossa S.D. Fatigue in prostate cancer survivors treated with definitive radiotherapy and LHRH analogs. Prostate 2010, 70:1480-1489.
41. Li Z.G., Danis V.A., Brooks P.M. Effect of gonadal steroids on the production of IL-1 and IL-6 by blood mononuclear cells in vitro. Clin. Exp. Rheumatol. 1993, 11:157-162.
42. Maggio M., Basaria S., Ble A., Lauretani F., Bandinelli S., Ceda G.P., Valenti G., Ling S.M., Ferrucci L. Correlation between testosterone and the inflammatory marker soluble interleukin-6 receptor in older men. J. Clin. Endocrinol. Metab. 2006, 91:345-347.
43. Malik U.R., Makower D.F., Wadler S. Interferon-mediated fatigue. Cancer 2001, 92:1664-1668.
44. Miaskowski C., Dodd M., Lee K., West C., Paul S.M., Cooper B.A., Wara W., Swift P.S., Dunn L.B., Aouizerat B.E. Preliminary evidence of an association between a functional interleukin-6 polymorphism and fatigue and sleep disturbance in oncology patients and their family caregivers. J. Pain Symptom Manage. 2010, 40:531-544.
45. Musabak U., Bolu E., Ozata M., Oktenli C., Sengul A., Inal A., Yesilova Z., Kilciler G., Ozdemir I.C., Kocar I.H. Gonadotropin treatment restores in vitro interleukin-1beta and tumour necrosis factor-alpha production by stimulated peripheral blood mononuclear cells from patients with idiopathic hypogonadotropic hypogonadism. Clin. Exp. Immunol. 2003, 132:265-270.
46. The Nation's Investment in Cancer Research 2009 2008, National Cancer Institute, The National Cancer Institute, Bethesda, MD.
47. National Comphrehensive Cancer Network, 2011. NCCN Guidelines Prostate Cancer Version 4.2011. From <> (retrieved 29.09.11). http://www.nccn.org.
48. National Institute of Environmental Health Sciences, 2011. SNPInfo. From <> (retrieved 12.10.11). http://snpinfo.niehs.nih.gov/snpfunc.htm.
49. Nettleship J.E., Pugh P.J., Channer K.S., Jones T., Jones R.D. Inverse relationship between serum levels of interleukin-1beta and testosterone in men with stable coronary artery disease. Horm. Metab. Res. 2007, 39:366-371.
50. O'Connor M.F., Bower J.E., Cho H.J., Creswell J.D., Dimitrov S., Hamby M.E., Hoyt M.A., Martin J.L., Robles T.F., Sloan E.K., Thomas K.S., Irwin M.R. To assess, to control, to exclude: effects of biobehavioral factors on circulating inflammatory markers. Brain Behav. Immun. 2009, 23:887-897.
51. Radloff L.S. The CES-D Scale: a self report depression scale for research in the general population. Appl. Psychol. Meas. 1977, 1:119-135.
52. Rausch S.M., Clark M.M., Patten C., Liu H., Felten S., Li Y., Sloan J., Yang P. Relationship between cytokine gene single nucleotide polymorphisms and symptom burden and quality of life in lung cancer survivors. Cancer 2010, 116:4103-4113.
53. Ravaglia G., Forti P., Maioli F., Chiappelli M., Dolzani P., Martelli M., Bianchin M., Mariani E., Bolondi L., Licastro F. Associations of the -174 G/C interleukin-6 gene promoter polymorphism with serum interleukin 6 and mortality in the elderly. Biogerontology 2005, 6:415-423.
54. Reinertsen K.V., Grenaker Alnaes G.I., Landmark-Hoyvik H., Loge J.H., Wist E., Kristensen V.N., Fossa S.D., Edvardsen H. Fatigued breast cancer survivors and gene polymorphisms in the inflammatory pathway. Brain Behav. Immun. 2011, 25:1376-1383.
55. Rettew J.A., Huet-Hudson Y.M., Marriott I. Testosterone reduces macrophage expression in the mouse of toll-like receptor 4, a trigger for inflammation and innate immunity. Biol. Reprod. 2008, 78:432-437.
56. Schubert C., Hong S., Natarajan L., Mills P.J., Dimsdale J.E. The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav. Immun. 2007, 21:413-427.
57. Spinedi E., Suescun M.O., Hadid R., Daneva T., Gaillard R.C. Effects of gonadectomy and sex hormone therapy on the endotoxin-stimulated hypothalamo-pituitary-adrenal axis: evidence for a neuroendocrine-immunological sexual dimorphism. Endocrinology 1992, 131:2430-2436.
58. Storey D.J., McLaren D.B., Atkinson M.A., Butcher I., Frew L.C., Smyth J.F., Sharpe M. Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy. Ann. Oncol 2011.
59. Storey D.J., McLaren D.B., Atkinson M.A., Butcher I., Liggatt S., O'Dea R., Smyth J.F., Sharpe M. Clinically relevant fatigue in recurrence-free prostate cancer survivors. Ann. Oncol. 2012, 23:65-72.
60. Van Vliet M., Spruit M.A., Verleden G., Kasran A., Van Herck E., Pitta F., Bouillon R., Decramer M. Hypogonadism, quadriceps weakness, and exercise intolerance in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2005, 172:1105-1111.
61. Viselli S.M., Olsen N.J., Shults K., Steizer G., Kovacs W.J. Immunochemical and flow cytometric analysis of androgen receptor expression in thymocytes. Mol. Cell. Endocrinol. 1995, 109:19-26.
62. Walston J., Arking D.E., Fallin D., Li T., Beamer B., Xue Q., Ferrucci L., Fried L.P., Chakravarti A. IL-6 gene variation is not associated with increased serum levels of IL-6, muscle, weakness, or frailty in older women. Exp. Gerontol. 2005, 40:344-352.
63. Wang X.S., Shi Q., Williams L.A., Mao L., Cleeland C.S., Komaki R.R., Mobley G.M., Liao Z. Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behav. Immun. 2010, 24:968-974.
64. Wilson A.G., Symons J.A., McDowell T.L., McDevitt H.O., Duff G.W. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc. Natl. Acad. Sci. USA 1997, 94:3195-3199.
65. Wratten C., Kilmurray J., Nash S., Seldon M., Hamilton C.S., O'Brien P.C., Denham J.W. Fatigue during breast radiotherapy and its relationship to biological factors. Int. J. Radiat. Oncol. Biol. Phys. 2004, 59:160-167.
66. Wunderlich F., Benten W.P., Lieberherr M., Guo Z., Stamm O., Wrehlke C., Sekeris C.E., Mossmann H. Testosterone signaling in T cells and macrophages. Steroids 2002, 67:535-538.
67. Yang Y.M., Lv X.Y., Huang W.D., Xu Z.R., Wu L.J. Study of androgen and atherosclerosis in old-age male. J. Zhejiang Univ. Sci. B 2005, 6:931-935.